CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 5,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of CG Oncology stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total transaction of $350,000.00. Following the sale, the director owned 5,000 shares in the company, valued at $350,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CG Oncology Stock Up 6.0%

CG Oncology stock traded up $4.12 on Thursday, hitting $72.84. The company’s stock had a trading volume of 1,346,084 shares, compared to its average volume of 1,183,786. CG Oncology, Inc. has a one year low of $23.65 and a one year high of $75.50. The firm has a market cap of $6.42 billion, a P/E ratio of -31.26 and a beta of 0.31. The company has a fifty day moving average price of $64.21 and a 200-day moving average price of $57.70.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. Analysts anticipate that CG Oncology, Inc. will post -2.89 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Whittier Trust Co. of Nevada Inc. acquired a new stake in CG Oncology during the 4th quarter valued at $27,000. NFSG Corp acquired a new position in CG Oncology in the first quarter worth $34,000. Comerica Bank boosted its stake in CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares in the last quarter. Fifth Third Bancorp bought a new stake in shares of CG Oncology during the first quarter worth $74,000. Finally, KBC Group NV bought a new stake in shares of CG Oncology during the first quarter worth $78,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CGON has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Wolfe Research started coverage on CG Oncology in a research report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Truist Financial reiterated a “buy” rating and set a $82.00 price objective (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a report on Monday, May 18th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $81.73.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.